Boston Scientific lands in Paris the week of EuroPCR and a Class I recall

Boston Scientific flew from Providence to Paris on Monday, May 18, 2026, flying N650BS from Rhode Island T. F. Green International Airport to Le Bourget in 6 hours 35 minutes. The flight arrived just before 10 a.m. local time, a direct overnight hop across the Atlantic for the Marlborough, Massachusetts-based medical device giant.

The same week, the company is presenting late-breaking clinical data at the EuroPCR conference in Paris — including TAVR results for its second-generation Acurate Neo2 valve, which showed a threefold reduction in paravalvular leakage, per a BioWorld report published May 17. The conference runs through May 19. Meanwhile, the U.S. Food and Drug Administration just classified a March 2026 advisory on Boston Scientific's Accolade pacemakers as a Class I recall correction, expanding the scope of affected devices and linking them to four deaths and more than 2,500 serious injuries as of March 18, per an FDA notice covered by MassDevice Network. The timing puts executive leadership in Europe at a moment when both clinical wins and safety scrutiny are top of mind.

The trip follows a pattern of conference-driven travel: Boston Scientific's jet visited Minneapolis on May 12, Seattle on May 5, and Newark on May 7. But the Paris stop overlaps directly with EuroPCR, the largest European cardiovascular meeting, where CEO Mike Mahoney's team is fielding questions on the latest stent and pulsed-field ablation data while also managing the fallout from a high-profile recall.